Core Points - The company is established as a joint-stock limited company in accordance with the Company Law of the People's Republic of China and other relevant regulations [4][6] - The registered capital of the company is RMB 291.707120 million [4] - The company was approved by the State-owned Assets Supervision and Administration Commission and registered in Beijing [4][6] - The company aims to utilize a sound operating mechanism to promote sustainable development and provide good returns to shareholders [6][7] Chapter Summaries Chapter 1: General Provisions - The company is established to protect the legal rights of shareholders, employees, and creditors [4] - The company was listed on the Shenzhen Stock Exchange on August 18, 2010, with an initial public offering of 40 million shares [4] - The legal representative of the company is the chairman, who is responsible for civil activities conducted in the company's name [5][6] Chapter 2: Business Objectives and Scope - The company's business objective is to promote the modernization and internationalization of the pharmaceutical industry in China [6] - The business scope includes the sale of various pharmaceutical products, medical devices, and food products [7] Chapter 3: Shares - The company issues shares in the form of stocks, with a par value of RMB 1.00 per share [8][9] - The total number of issued shares is 291.707120 million [8] Chapter 4: Party Committee - The company has established a Party Committee to ensure the implementation of national policies and oversee major decisions [14][15] Chapter 5: Shareholders and Shareholders' Meeting - The company maintains a shareholder register based on the records provided by the securities registration and settlement institution [16] - Shareholders have rights to dividends, attend meetings, and supervise the company's operations [16][17] - The company must hold an annual shareholders' meeting within six months after the end of the fiscal year [25][50] Chapter 6: Shareholders' Meeting Procedures - The company must notify shareholders of meetings at least 20 days in advance for annual meetings and 15 days for temporary meetings [62][63] - The meeting must be presided over by the chairman or a designated representative [74] Chapter 7: Voting and Resolutions - Resolutions can be classified as ordinary or special, with different voting thresholds required for approval [82][84] - Ordinary resolutions require a simple majority, while special resolutions require two-thirds of the voting rights [82][84]

Summary of Key Points Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. plans to provide a guarantee for its subsidiary, Anshun Dajiankang Pharmaceutical Industry Operation Co., Ltd., to secure a loan of 148 million yuan from Guizhou Bank for a period of 2 years, reflecting the company's support for its subsidiary's operational needs and long-term business development [1][4]. Group 1: Guarantee Details - The subsidiary, Anshun Dajiankang, is applying for a loan of 148 million yuan, with the company providing a guarantee of 81.4 million yuan based on its 55% ownership stake [1][4]. - The other shareholder, Anshun Medical Investment Technology Service Co., Ltd., will provide a guarantee of 66.6 million yuan based on its 45% ownership stake [4]. - The board of directors has approved the guarantee, which will be submitted for shareholder meeting review [1][2]. Group 2: Financial Position - After this guarantee, the total amount of external guarantees provided by the company and its subsidiaries will be 213.4 million yuan, which is 6.71% of the company's most recent audited net assets [4]. - The guarantees provided to external entities outside the consolidated statements amount to 24.5 million yuan, representing 0.77% of the company's most recent audited net assets [4]. - The guarantees to the subsidiary total 188.9 million yuan, accounting for 5.94% of the company's most recent audited net assets [4]. Group 3: Company and Subsidiary Information - Anshun Dajiankang was established on May 30, 2003, with a registered capital of 10 million yuan and operates in various pharmaceutical and health-related sectors [2]. - The company has a good operational and credit status, indicating its capability to repay the loan [4].